Levofloxacin

Fluoroquinolone antibiotic, Antibacterial

Levofloxacin

Levaquin (US brand discontinued); generic and ophthalmic Quixin/Iquix

Experience

👥 No personal reports yet

⚕ No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary

Classes

Fluoroquinolone antibiotic, Antibacterial

Common uses

Community-acquired pneumonia0, Acute bacterial sinusitis0, Complicated UTI / pyelonephritis0, Bacterial prostatitis0, Anthrax prophylaxis and treatment0, Bacterial conjunctivitis/keratitis (topical)0

Pharmacy

Starting dose

500-750 mg PO/IV once daily

Preparations

250, 500, 750 mg tablets; 25 mg/mL oral solution; 25 mg/mL IV (premix bags 250, 500, 750 mg); 0.5%, 1.5% ophthalmic solutions

US FDA Max

750 mg/d

Pharmacology

Routes

Oral, IV, topical ophthalmic

Onset

Hours

Duration

24 hours

Half-life

~6-8 hours^[1]

Bioavailability

~99% (oral; matched 1:1 IV-to-PO conversion)^[1]

Pregnancy

Avoid in pregnancy where alternatives exist (animal cartilage toxicity; class-wide concern).^{[citation needed]}

Legal status

Rx-only in US. Carries the same fluoroquinolone-class Boxed Warnings as ciprofloxacin: tendinitis/tendon rupture (especially elderly, corticosteroid co-use), peripheral neuropathy, CNS effects, worsening of myasthenia gravis^[1]

Purported mechanism

Levofloxacin (the L-enantiomer of ofloxacin) inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking supercoiling and decatenation required for DNA replication; the result is bactericidal.0 Among "respiratory fluoroquinolones" (with moxifloxacin and gemifloxacin) — broader S. pneumoniae and atypical coverage than ciprofloxacin, making it more useful in CAP. QT prolongation, hypoglycemia, and aortic dissection signals are recognized class effects^[1].

References

↑ ^1.0 ^1.1 ^1.2 ^1.3 FDA Prescribing Information, Levaquin (levofloxacin), Janssen, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s072,020635s075,021721s041lbl.pdf

[levaquin-label-1] 1.0 ^1.1 ^1.2 ^1.3 FDA Prescribing Information, Levaquin (levofloxacin), Janssen, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s072,020635s075,021721s041lbl.pdf

[1]